SBFM — Sunshine Biopharma Income Statement
0.000.00%
- $6.88m
- -$10.54m
- $24.09m
- 21
- 78
- 14
- 31
Annual income statement for Sunshine Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.021 | 0.071 | 0.228 | 4.35 | 24.1 |
Cost of Revenue | |||||
Gross Profit | 0.01 | 0.046 | 0.111 | 1.7 | 8.34 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.97 | 2.7 | 12.3 | 31.3 | 28.9 |
Operating Profit | -0.948 | -2.63 | -12.1 | -27 | -4.79 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.08 | -2.78 | -12.4 | -26.5 | -4.11 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.08 | -2.78 | -12.4 | -26.7 | -4.51 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -1.66 | -2.78 | -12.4 | -26.7 | -4.51 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.66 | -2.78 | -12.4 | -26.7 | -4.51 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,215 | -72 | -106 | -97.7 | -18.5 |